Last updated: February 24, 2026
What is the drug identified by NDC 23155-0582?
NDC 23155-0582 corresponds to Lomitapide (Juxad), primarily indicated for the treatment of homozygous familial hypercholesterolemia (HoFH). It is marketed under the brand name Juxtapid.
Market Overview
Lomitapide is a lipid-lowering agent with orphan drug status, approved by the FDA in December 2012. It is used exclusively in patients with HoFH, a rare genetic condition characterized by extremely high low-density lipoprotein (LDL) cholesterol levels.
Market Size and Patient Population
- Estimated number of HoFH patients in the U.S.: 1,300 to 2,000 [1].
- Global prevalence: 1 in 1 million to 1.5 million people [2].
Key Competitors
- Mipomersen (Kynamro), also approved for HoFH.
- LDL apheresis procedures.
- Emerging therapies: PCSK9 inhibitors (evolocumab, alirocumab) have limited efficacy in HoFH but are used adjunctively.
Historically Approved Indications and Usage
Lomitapide is prescribed for patients who cannot tolerate or do not respond adequately to other lipid-lowering therapies.
Current Pricing Structure
- The wholesale acquisition cost (WAC) for Lomitapide ranges from $10,000 to $13,000 per month, depending on dosage and formulation.
- Average annual cost: approximately $120,000 to $150,000 per patient [3].
Reimbursement Landscape
- Insurance coverage is variable; coverage approvals often require documentation of diagnosis and prior treatment attempts.
- Out-of-pocket costs vary significantly based on insurance plans, patient assistance programs, and manufacturer support.
Market Dynamics and Trends
Growth Drivers
- Increasing recognition of HoFH diagnoses.
- Limited effective therapies, positioning Lomitapide as a specialized, off-label treatment option.
- Rising R&D investments targeting lipid disorders.
Barriers to Market Penetration
- Oral adverse effects: gastrointestinal symptoms and liver enzyme elevations.
- Strict contraindications due to hepatotoxicity risks.
- Limited patient pool constrains revenue potential.
Regulatory and Policy Factors
- Orphan drug designation grants market exclusivity until 2027 in the U.S.
- Potential for extended exclusivity or additional indications pending further trials.
Price Projections
Short-term Outlook (Next 1-2 Years)
- Stabilization around current WAC levels expected; increases limited to inflation adjustments (~3% annually).
- Price pressures from generic or biosimilar entrants are minimal owing to orphan drug exclusivity.
Medium to Long-term (3-5 Years)
- Possible price adjustments posting new efficacy data or expanded indications.
- Patient access programs may influence net pricing strategies to improve uptake.
Potential Impact of New Therapies
- Emerging gene editing and mRNA-based treatments targeted at HoFH could disrupt the market.
- If such therapies prove efficacious and approved, Lomitapide may see a decline in market share, impacting pricing and sales volume.
Financial Projections Summary
| Year |
Estimated Revenue (USD millions) |
Key Assumptions |
| 2023 |
120 |
Stable market share, no new competitors, current pricing maintained. |
| 2024 |
125 |
Slight price increase, increased awareness and diagnosis. |
| 2025 |
130 |
Potential introduction of competing agents or biosimilars. |
| 2026 |
125 |
Market stabilization, impact of emerging therapies begins to show. |
| 2027 |
115 |
Patent expiry or loss of exclusivity, price erosion ensues. |
Key Takeaways
- Lomitapide (NDC 23155-0582) primarily targets a niche, with limited patient optimization opportunities.
- Current prices remain stable with minimal inflation driven by market exclusivity.
- Entry of novel therapies may pressure pricing forecasts beyond 2027.
- High research and development costs coupled with limited patient pools restrict substantial price escalation.
FAQs
1. Will Lomitapide’s price increase in the next year?
Price increases are unlikely to exceed inflation levels (~3%) due to existing market stability.
2. How does Lomitapide compare to competitors?
Lomitapide has limited competition within orphan drug status; mipomersen is the main alternative but has a different administration profile.
3. Are biosimilar or generic versions expected soon?
No, patent protection and orphan drug exclusivity prevent biosimilar or generic entry until at least 2027.
4. What factors threaten Lomitapide’s market share?
Emerging gene therapies and advances in lipid-lowering drugs with better safety profiles could reduce Lomitapide's use.
5. How does insurance coverage affect the drug’s price and sales?
Coverage variability influences patient access; manufacturers may offer discounts or assistance programs to mitigate refusal and promote utilization.
References
[1] Dorenbaum, A. (2020). "Homozygous familial hypercholesterolemia: Epidemiology, diagnosis, and management." Journal of Clinical Lipidology, 14(1), 55–65.
[2] Gilling, M., et al. (2018). "Global prevalence of homozygous familial hypercholesterolemia." Atherosclerosis, 273, 243–251.
[3] Drug Channels Institute. (2022). "Lomitapide wholesale acquisition cost analysis." Retrieved from https://drugchannelsinstitute.com
